Adaptive Biotechnologies Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Adaptive Biotechnologies stock has a consensus rating of "Buy" and an average price target of $25.07. The average 1-year stock price forecast is 1.65% lower than the current stock price, while the lowest is $21 (-17.61%) and the highest is $28 (+9.85%).

Price Target: $25.07 (-1.65%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$21	$25.07	$25	$28
Change	-17.61%	-1.65%	-1.92%	+9.85%

Analyst Ratings

The average analyst rating for Adaptive Biotechnologies stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jun '26	Jul '26	Aug '26
Strong Buy	5	5	5	5	5	5
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
David Westenberg Piper Sandler	Piper Sandler	Buy Reiterates $20 → $28	Buy	Reiterates	$20 → $28	+7.89%	Aug 4, 2026
William Bonello Craig-Hallum	Craig-Hallum	Buy Maintains $21	Buy	Maintains	$21	-17.61%	Jul 30, 2026
Sebastian Sandler J.P. Morgan	J.P. Morgan	Buy Maintains $25 → $27	Buy	Maintains	$25 → $27	+5.92%	Jul 30, 2026
Kallum Titchmarsh Morgan Stanley	Morgan Stanley	Hold Maintains $20 → $22	Hold	Maintains	$20 → $22	-13.69%	Jul 30, 2026
Subbu Nambi Guggenheim	Guggenheim	Buy Reiterates $22 → $25	Buy	Reiterates	$22 → $25	-1.92%	Jul 30, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

293.24M

from 276.98M

5.87%

from 276.98M

Revenue Next Year

358.54M

from 293.24M

22.27%

from 293.24M

EPS This Year

-0.54

from -0.39

EPS Next Year

-0.18

from -0.54

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	154.34M	185.31M	170.28M	178.96M	276.98M	293.24M
Revenue Growth	56.88%	20.06%	-8.11%	5.10%	54.77%	5.87%
Operating Income	-208.97M	-200.19M	-201.61M	-155.34M	-57.12M	-60.81M
Net Income	-207.28M	-200.19M	-225.25M	-159.49M	-59.50M	-85.78M
EPS	-	-	-	-	-0.39	-0.54
Free Cash Flow	-139.10M	-90.17M	-81.95M	-24.48M	950.88K	-5.00M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	296.9M
Avg	293.2M
Low	290.6M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	7.2%
Avg	5.9%
Low	4.9%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.51
Avg	-0.54
Low	-0.56

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-